The MSC Phenotyping Cocktail Kit, anti-human, REAfinity enables the fast and standardized characterization and quantification of cultured human MSCs by flow cytometry based on the defined ISCT standards. The kit includes a set of ISCT proposed positive and negative markers as a ready-to-use phenotyping cocktail and also a corresponding isotype control cocktail. To ensure superior lot-to-lot consistency, low background, and high staining specificity the kit applies recombinantly engineered REAfinity antibodies.
For this Kit, an Express Mode add-on module for the MACSQuantify™ software
Related products for MSC Phenotyping Cocktail Kit, anti-human, REAfinity®
The MSC Phenotyping Cocktail Kit, anti-human, REAfinity enables the fast and standardized characterization and quantification of cultured human MSCs by flow cytometry based on the defined ISCT standards. The kit includes a set of ISCT proposed positive and negative markers as a ready-to-use phenotyping cocktail and also a corresponding isotype control cocktail. To ensure superior lot-to-lot consistency, low background, and high staining specificity the kit applies recombinantly engineered REAfinity antibodies.
For this Kit, an Express Mode add-on module for the MACSQuantify™ software is offered, designed to simplify and standardize the identification of mesenchymal stem cells (MSCs) on the MACSQuant® Analyzer by automated gating and data analysis: MSC Phenotyping Kit Express Mode
MSC Phenotyping Cocktail, anti-human, REAfinity containing:
- CD14 Antibody, anti-human, PE, REAfinity (clone: REA599)
- CD19 Antibody, anti-human, PE, REAfinity (clone: REA675)
- CD34 Antibody, anti-human, PE, REAfinity (clone: REA1164)
- CD45 Antibody, anti-human, PE, REAfinity (clone: REA747)
- CD73 Antibody, anti-human, APC, REAfinity (clone: REA804)
- CD90 Antibody, anti-human, FITC, REAfinity (clone: REA897)
- CD105 Antibody, anti-human, Vio® Bright V423, REAfinity (clone: REA794)
- HLA-DR Antibody, anti-human, VioGreen™, REAfinity (clone: REA805)
MSC Control Cocktail, anti-human, REAfinity containing:
- REA Control Antibody (S), human IgG1, FITC, REAfinity (clone: REA293)
- REA Control Antibody (S), human IgG1, PE, REAfinity (clone: REA293)
- REA Control Antibody (S), human IgG1, APC, REAfinity (clone: REA293)
- REA Control Antibody (S), human IgG1, Vio® Bright V423, REAfinity (clone: REA293)
- REA Control Antibody (S), human IgG1, VioGreen, REAfinity (clone: REA293)
CD73 Antibody, anti-human, APC, REAfinity (clone: REA804)
CD73 Antibody, anti-human, PE, REAfinity (clone: REA804)
CD90 Antibody, anti-human, FITC, REAfinity (clone: REA897)
CD105 Antibody, anti-human, Vio® Bright V423, REAfinity (clone: REA794)
CD73 Antibody, anti-human, Biotin, REAfinity (clone: REA804)
Biotin Antibody, anti-human, VioGreen, REAfinity (clone: REA746)
Instrument details
Flow cytometer equipped with a red (640 nm), a blue (488 nm), and a violet (405 nm) laser.
Cultured bone marrow derived MSCs were stained with the MSC Phenotyping Cocktail Kit, anti-human, REAfinity and Propidium iodide (PI) for dead cell exclusion. Cells were analyzed by flow cytometry using the MACSQuant® Analyzer 10. As a preliminary step for exclusion of debris a gate in forward scatter (FSC) versus side scatter (SSC) was set (A). A gate for viable cells (B) as well as for exclusion of doublets in forward scatter height (FSC-H) versus forward scatter area (FSC-A) (C) was set. Cells were analyzed for expression of CD73 (D), CD90 (E), CD105 (F), non-MSC markers (CD14, CD19, CD34, CD45) (G), and HLA-DR (H). Each histogram was overlaid with the corresponding isotype control (grey curves) to identify positively stained cells.
Aliquot 1 of cultured MSCs was stained with the MSC Phenotyping Cocktail and aliquot 2 with the Isotype Control Cocktail. The fractions were analyzed by flow cytometry using the MACSQuant® Analyzer 10. Each histogram was overlaid with the corresponding isotype control to identify positively stained cells. In order to distinguish between activated MSC and non-MSCs, the HLA-DR antibody (conjugated to different fluorochromes) has been used in combination with other MSC-negative markers.
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Kolle, S.-F. A. et al. (2020) Ex vivo‐expanded autologous adipose tissue‐derived stromal cells ensure enhanced fat graft retention in breast augmentation: A randomized controlled clinical trial. Stem Cells Transl Med 9 (11): 1277-1286
- Egger, D. et al. (2019) From 3D to 3D: isolation of mesenchymal stem/stromal cells into a three-dimensional human platelet lysate matrix. Stem Cell Res Ther. 10: 248
- Dominici, M. et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317
- Damerau, A. et al. (2021) A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro. Int J Mol Sci 22 (1): 128
- Rahman, M. S. et al. (2020) The FGF, TGFβ and WNT axis Modulate Self-renewal of Human SIX2+ Urine Derived Renal Progenitor Cells. Sci Rep 10: 739
- Jungbluth, P. et al. (2019) Human iPSC-derived iMSCs improve bone regeneration in mini-pigs. Bone Res. 7: 32
- Sekine, K. et al. (2020) Generation of human induced pluripotent stem cell-derived liver buds with chemically defined and animal origin-free media. Sci Rep 10: 17937
- Gaber, T. et al. (2020) Synaptotagmin-13 Is a Neuroendocrine Marker in Brain, Intestine and Pancreas. Int J Mol Sci 21 (3): 865
- Widholz, B. et al. (2019) Pooling of Patient-Derived Mesenchymal Stromal Cells Reduces Inter-Individual Confounder-Associated Variation without Negative Impact on Cell Viability, Proliferation and Osteogenic Differentiation. Cells 8 (6): 633
- Ling, J. et al. (2020) Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans. Stem Cell Reports 14 (1): 105-121
- Ho, Y. K. et al. (2020) A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy. Sci Rep 10: 14257
- Chan, C. et al. (2021) Co-localisation of intra-nuclear membrane type-1 matrix metalloproteinase and hypoxia inducible factor-2α in osteosarcoma and prostate carcinoma cells. Oncol Lett 21 (2): 158
- Gutermuth, A. et al. (2019) Descemet's Membrane Biomimetic Microtopography Differentiates Human Mesenchymal Stem Cells Into Corneal Endothelial-Like Cells. Cornea 38 (1): 110
- Hernández, J. J. et al. (2021) Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. J. Transl. Med. 19: 149
- Le Naour, A. et al. (2020) Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. J. Mol. Cell Biol. 12 (3): 202
- Sekine, K. et al. (2020) Robust detection of undifferentiated iPSC among differentiated cells. Sci Rep 10: 10293
- Eremichev, R. et al. (2021) Scar-Free Healing of Endometrium: Tissue-Specific Program of Stromal Cells and Its Induction by Soluble Factors Produced After Damage. Front Cell Dev Biol. (9)
You have previously chosen International as your location.
What do you want to do?